Cardiovascular Drugs and Therapy

, Volume 24, Issue 1, pp 71–75 | Cite as

Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment

  • Robert S. Rosenson


Residual cardiovascular risk associated with low levels of HDL was a major theme at the American Heart Association’s 2009 Scientific Sessions. The presentations on HDL biology encompassed a broad spectrum of investigations that ranged from population-based studies, anti-atherothrombotic mechanisms of HDL particles, and therapeutic approaches to raising HDL cholesterol levels. This meeting highlight reviews some of the most important presentations that serve to enhance our knowledge in areas that extend beyond measurement of HDL cholesterol or apolipoprotein A-I concentration to precise mechanisms that elucidate functional aspects of HDL particles.

HDL cholesterol and cardiovascular risk

Low levels of HDL cholesterol are inversely related to the risk of coronary heart disease; however the additive contribution of HDL cholesterol and apolipoprotein A-I (apo A-I) in individuals with varying levels of LDL cholesterol (LDL-C) is less well established. In the Women’s Health...

Key words

High density lipoprotein Cholesterol ester transfer protein Cholesterol ester transfer protein inhibitors Dalcetrapib Torcetrapib Niacin Cardiovascular disease 


  1. 1.
    Mora S, Cui Y, Ridker PM. Association of HDL cholesterol and apolipoprotein A-I with incident CVD across levels of LDL cholesterol in 27, 748 women. Circulation. 2009;120:S507.CrossRefGoogle Scholar
  2. 2.
    Frikke-Schmidt R et al. Cholesterol ester transfer protein genotype predicts anti-atherogenic lipid profile and decreased risk of ischemic heart disease, ischemic cerebrovascular disease, and death not attributable to HDL cholesterol alone. Circulation. 2009;120:S1175.Google Scholar
  3. 3.
    Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Vasquez E, Sethi AA, Sampson M, Remaly AT, Chaudry H. O Cannon III R. “Dysfunctional” high-density lipoprotein despite normal cholesterol content in sedentary obese women. Circulation. 2009;120:S470.Google Scholar
  5. 5.
    Khera AV, Rodriques A, de la Lioera-Moya M, Rothblatt GH, Rader DJ. Serum cholesterol efflux capacity, a measure of HDL-C quality, varies according to coronary artery disease status independently of HDL-C quantity. Circulation. 2009;120:S469.Google Scholar
  6. 6.
    Hara T, Ishida T, Kojima Y, Hirata K-I. Inactivation of endothelial lipase increases anti-inflammatory HDL particles. Circulation. 2009;120:S469.Google Scholar
  7. 7.
    Besler C, Heinrich K, Rohrer L, Yonekawa K, Doerriers C, Manes C, et al. Mechanisms leading to impaired endothelial-vasoprotective properties of high density lipoprotein (HDL) in patients with coronary disease (CAD). Circulation. 2009;120:S1009.Google Scholar
  8. 8.
    Holy E, Stampfli SF, Akhmedov A, Camici G, Luscher TF, Tanner FC. High-density lipoprotein (HDL) from healthy subjects, but not from patients with coronary artery disease, exerts anti-thrombotic effects on human endothelial cells. Circulation. 2009;120:S1099.CrossRefGoogle Scholar
  9. 9.
    Drew BG, Duffy SJ, Forbes JM, Chin-Dusting J, Kaye DM, Kemp BE, et al. High density lipoprotein modulates glucose metabolism by multiple mechanisms. Circulation. 2009;120:S468.Google Scholar
  10. 10.
    Barter PJ, Caulfield M, Eriksson M, Griudy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Stroes ESG, Kastelein JJP, Benardeau A, Kuhlmann O, Blum D, Campos LA, et al. B J Pharmacol. 2009;158:1763–70.CrossRefGoogle Scholar
  12. 12.
    Maugeais C, Magg C, Dernick G, Matile H, von der Mark E, Pflieger P, et al. Dalcetrapib binds to and changes the conformation of CETP in a unique manner (differing to that observed with torcetrapib). Circulation. 2009;120:S445.CrossRefGoogle Scholar
  13. 13.
    Niesor EJ, Okamoto H, Naugeais C, von der Mark E, Brousse M, Blum-Kaelin D, et al. The effects of dalcetrapib on macrophage reverse cholesterol transport in a rodent model. Circulation. 2009;120:S468.Google Scholar
  14. 14.
    Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)- 6-HDL and LDL treatment strategies in atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21:221–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Taylor AJ, Villnes TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. N Engl J Med. 2009;361:2113–22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.SUNY DownstateBrooklynUSA

Personalised recommendations